Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
The International Journal of Biochemistry & Cell Biology
|
April 11, 2008
Overcoming kinase resistance in chronic myeloid leukemia
Francis Lee, Abderrahim Fandi, Maurizio Voi
Clinical Lung Cancer
|
June 10, 2005
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer
Christian Manegold, Ulrich Gatzemeier, Erika Buchholz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 2, 2013
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer
Peter M Ellis, Ulf Jungnelius, Jennie Zhang, et al.
Oncology Reports
|
January 19, 2008
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines
Fabio Timeus, Nicoletta Crescenzio, Abderrahim Fandi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2007
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients
Jean-Louis Pujol, Patrick Viens, Paul Rebattu, et al.
Journal of Cancer Research and Clinical Oncology
|
September 13, 2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Giuseppe Giaccone, Renee B Iacona, Abderrahim Fandi, et al.
European Urology
|
October 27, 2015
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Guru Sonpavde, Gregory R Pond, Arnoud J Templeton, et al.
Clinical Breast Cancer
|
April 29, 2018
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis
Javier Cortes, José Pérez-García, Scott Whiting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
Primo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
Benjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
The International Journal of Biochemistry & Cell Biology
|
April 11, 2008
Overcoming kinase resistance in chronic myeloid leukemia
Francis Lee, Abderrahim Fandi, Maurizio Voi
Clinical Lung Cancer
|
June 10, 2005
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer
Christian Manegold, Ulrich Gatzemeier, Erika Buchholz, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 2, 2013
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer
Peter M Ellis, Ulf Jungnelius, Jennie Zhang, et al.
Oncology Reports
|
January 19, 2008
In vitro antiproliferative and antimigratory activity of dasatinib in neuroblastoma and Ewing sarcoma cell lines
Fabio Timeus, Nicoletta Crescenzio, Abderrahim Fandi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2007
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients
Jean-Louis Pujol, Patrick Viens, Paul Rebattu, et al.
Journal of Cancer Research and Clinical Oncology
|
September 13, 2008
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy
Giuseppe Giaccone, Renee B Iacona, Abderrahim Fandi, et al.
European Urology
|
October 27, 2015
Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel
Guru Sonpavde, Gregory R Pond, Arnoud J Templeton, et al.
Clinical Breast Cancer
|
April 29, 2018
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis
Javier Cortes, José Pérez-García, Scott Whiting, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2011
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer
Primo N Lara, Jean-Yves Douillard, Kazuhiko Nakagawa, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer
Benjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.
Page
of 2